Align Technology (ALGN)
(Delayed Data from NSDQ)
$212.15 USD
+1.37 (0.65%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $211.69 -0.46 (-0.22%) 5:08 PM ET
4-Sell of 5 4
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$212.15 USD
+1.37 (0.65%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $211.69 -0.46 (-0.22%) 5:08 PM ET
4-Sell of 5 4
C Value B Growth C Momentum C VGM
Zacks News
Alcon (ALC) Gains From Growing Market Demand, New Launches
by Zacks Equity Research
Within Vision Care, Alcon (ALC) is registering solid growth, banking on strong sales of its contact lenses and ocular health products.
ZimVie (ZIMV) Progresses in Dental Space With Biotivity Launch
by Zacks Equity Research
ZimVie's (ZIMV) Biotivity A/C Plus Membrane is a barrier membrane that contains an array of growth factors.
Walgreens Boots (WBA) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots (WBA) Q4 retail revenues are impacted by macroeconomic-driven consumer pressure and lower COVID-19 OTC test kit sales.
Here's Why You Should Hold on to Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN), driven by strong vascular and neuro businesses.
Hologic (HOLX) to Elevate OB-GYN Training With New Partnerships
by Zacks Equity Research
Hologic's (HOLX) collaboration with AAGL and Inovus Medical is likely to optimize OB-GYN training for minimally invasive surgeries.
Here's Why Investors Should Buy Bruker (BRKR) Stock Now
by Zacks Equity Research
The strong prospects of the BSI BioSpin and CALID group are likely to bode well for Bruker (BRKR) stock.
Neogen's (NEOG) Q1 Earnings Miss Estimates, Margins Rise
by Zacks Equity Research
Neogen's (NEOG) Q1 Animal Safety business experiences continued destocking, with channel inventory levels reaching multi-year lows.
Haemonetics (HAE) Announces Agreement to Acquire OpSens
by Zacks Equity Research
Haemonetics' (HAE) acquisition of OpSens will expand its leadership in the interventional cardiology market.
Here's Why You Should Invest in Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on consistent growth and upbeat guidance.
Alcon (ALC) Expands Optical Care Line With Latest Launch
by Zacks Equity Research
Alcon's (ALC) new TOTAL30 Multifocal lens outwits digital device dryness by delivering nearly 100% water at the lens's surface via a patented Water Gradient Technology.
After Plunging -11.1% in 4 Weeks, Here's Why the Trend Might Reverse for Align Technology (ALGN)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Align Technology (ALGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors remain optimistic about Exact Sciences (EXAS) due to its strategic prioritization and positive solvency.
Reasons to Add Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
NextGen's (NXGN) AI-Based Ambient Assist to Expedite Care Plans
by Zacks Equity Research
NextGen's (NXGN) Ambient Assist will help reduce significant time by summarizing appointments and preparing care plans using AI-driven technology in real time.
Thermo Fisher's (TMO) Strong End Markets and New Buyouts Aid
by Zacks Equity Research
Thermo Fisher (TMO) is registering strong growth in the electron microscopy and chromatography and mass spectrometry businesses in the academic and government end market.
Hyperfine (HYPR) Progresses in MRI Space With Latest FDA Nod
by Zacks Equity Research
Hyperfine's (HYPR) updated Swoop software is expected to make brain imaging more accessible and clinically relevant.
4 Stocks to Buy From the Prospering Dental Supplies Industry
by Indrajit Bandyopadhyay
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on robust RMS segment growth and upbeat guidance.
ResMed (RMD) Gains From Strong Device Sales Amid Macro Woes
by Zacks Equity Research
ResMed's (RMD) respiratory care business continues to drive growth and the adoption of bilevel and other non-invasive ventilator solutions worldwide.
enVVeno (NVNO) Plans to Expedite enVVe Development for CVI
by Zacks Equity Research
enVVeno (NVNO) notes that its capital position is now strong enough to begin the enVVe pivotal study.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX), led by growth in Vascular, Interventional and Surgical businesses.
DexCom (DXCM) to Launch Latest CGM System G7 in Canada
by Zacks Equity Research
DexCom's (DXCM) G7 CGM System (launched in Canada) is expected to combine simplicity and power, thereby providing a better way to manage diabetes.
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors remain optimistic about Tandem Diabetes (TNDM), backed by strategic developments and innovative new launches.
Quest Diagnostics (DGX) to Boost Lab Services With New Pact
by Zacks Equity Research
Quest Diagnostics (DGX) latest deal will boost dialysis laboratory testing and reduce the laboratory costs of dialysis programs for ESRD patients.
Here's Why You Should Add McKesson (MCK) to Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.